ADAR1 Capital Management »

Screaming Eagle Acq Class A shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Screaming Eagle Acq Class A (SCRM) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Screaming Eagle Acq Class A

Tip: Access up to 7 years of quarterly data

All positions including Screaming Eagle Acq Class A held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Screaming Eagle Acq Class A by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $318k 30k 10.60

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Royalty Pharma Shs Class A (RPRX)
Keros Therapeutics (KROS)
Roivant Sciences SHS (ROIV)
Cytokinetics Com New (CYTK)
Arbutus Biopharma (ABUS)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New (MACK)
Cerevel Therapeutics Hldng I (CERE)
Mirati Therapeutics
Merck & Co (MRK)
Ascendis Pharma A/s Sponsored Adr (ASND)
Immunovant (IMVT)
Viking Therapeutics (VKTX)
Protagonist Therapeutics (PTGX)

View all positions for ADAR1 Capital Management

Top funds holding Screaming Eagle Acq Class A

Aristeia Capital
Vivaldi Asset Management
Millennium Management
Westchester Capital Management
Schechter Investment Advisors
CNH Partners
HGC Investment Management
Berkley W R
Kepos Capital
Kim
Picton Mahoney Asset Management
TD Asset Management
Two Sigma Investments
Brooklyn Capital Management
Jpmorgan Chase & Co

View all funds holding Screaming Eagle Acq Class A